CL2022003296A1 - Anti-cd200r1 antibodies and methods of using the same - Google Patents
Anti-cd200r1 antibodies and methods of using the sameInfo
- Publication number
- CL2022003296A1 CL2022003296A1 CL2022003296A CL2022003296A CL2022003296A1 CL 2022003296 A1 CL2022003296 A1 CL 2022003296A1 CL 2022003296 A CL2022003296 A CL 2022003296A CL 2022003296 A CL2022003296 A CL 2022003296A CL 2022003296 A1 CL2022003296 A1 CL 2022003296A1
- Authority
- CL
- Chile
- Prior art keywords
- cd200r1
- antibodies
- methods
- present disclosure
- same
- Prior art date
Links
Classifications
-
- C—CHEMISTRY; METALLURGY
- C07—ORGANIC CHEMISTRY
- C07K—PEPTIDES
- C07K16/00—Immunoglobulins [IGs], e.g. monoclonal or polyclonal antibodies
- C07K16/18—Immunoglobulins [IGs], e.g. monoclonal or polyclonal antibodies against material from animals or humans
- C07K16/28—Immunoglobulins [IGs], e.g. monoclonal or polyclonal antibodies against material from animals or humans against receptors, cell surface antigens or cell surface determinants
- C07K16/2803—Immunoglobulins [IGs], e.g. monoclonal or polyclonal antibodies against material from animals or humans against receptors, cell surface antigens or cell surface determinants against the immunoglobulin superfamily
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P35/00—Antineoplastic agents
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K39/00—Medicinal preparations containing antigens or antibodies
- A61K2039/505—Medicinal preparations containing antigens or antibodies comprising antibodies
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K39/00—Medicinal preparations containing antigens or antibodies
- A61K2039/54—Medicinal preparations containing antigens or antibodies characterised by the route of administration
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K39/00—Medicinal preparations containing antigens or antibodies
- A61K2039/545—Medicinal preparations containing antigens or antibodies characterised by the dose, timing or administration schedule
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K39/00—Medicinal preparations containing antigens or antibodies
- A61K2039/57—Medicinal preparations containing antigens or antibodies characterised by the type of response, e.g. Th1, Th2
- A61K2039/572—Medicinal preparations containing antigens or antibodies characterised by the type of response, e.g. Th1, Th2 cytotoxic response
-
- C—CHEMISTRY; METALLURGY
- C07—ORGANIC CHEMISTRY
- C07K—PEPTIDES
- C07K2317/00—Immunoglobulins specific features
- C07K2317/20—Immunoglobulins specific features characterized by taxonomic origin
- C07K2317/24—Immunoglobulins specific features characterized by taxonomic origin containing regions, domains or residues from different species, e.g. chimeric, humanized or veneered
-
- C—CHEMISTRY; METALLURGY
- C07—ORGANIC CHEMISTRY
- C07K—PEPTIDES
- C07K2317/00—Immunoglobulins specific features
- C07K2317/30—Immunoglobulins specific features characterized by aspects of specificity or valency
- C07K2317/33—Crossreactivity, e.g. for species or epitope, or lack of said crossreactivity
-
- C—CHEMISTRY; METALLURGY
- C07—ORGANIC CHEMISTRY
- C07K—PEPTIDES
- C07K2317/00—Immunoglobulins specific features
- C07K2317/30—Immunoglobulins specific features characterized by aspects of specificity or valency
- C07K2317/34—Identification of a linear epitope shorter than 20 amino acid residues or of a conformational epitope defined by amino acid residues
-
- C—CHEMISTRY; METALLURGY
- C07—ORGANIC CHEMISTRY
- C07K—PEPTIDES
- C07K2317/00—Immunoglobulins specific features
- C07K2317/30—Immunoglobulins specific features characterized by aspects of specificity or valency
- C07K2317/35—Valency
-
- C—CHEMISTRY; METALLURGY
- C07—ORGANIC CHEMISTRY
- C07K—PEPTIDES
- C07K2317/00—Immunoglobulins specific features
- C07K2317/70—Immunoglobulins specific features characterized by effect upon binding to a cell or to an antigen
- C07K2317/73—Inducing cell death, e.g. apoptosis, necrosis or inhibition of cell proliferation
-
- C—CHEMISTRY; METALLURGY
- C07—ORGANIC CHEMISTRY
- C07K—PEPTIDES
- C07K2317/00—Immunoglobulins specific features
- C07K2317/70—Immunoglobulins specific features characterized by effect upon binding to a cell or to an antigen
- C07K2317/76—Antagonist effect on antigen, e.g. neutralization or inhibition of binding
-
- C—CHEMISTRY; METALLURGY
- C07—ORGANIC CHEMISTRY
- C07K—PEPTIDES
- C07K2317/00—Immunoglobulins specific features
- C07K2317/90—Immunoglobulins specific features characterized by (pharmaco)kinetic aspects or by stability of the immunoglobulin
- C07K2317/92—Affinity (KD), association rate (Ka), dissociation rate (Kd) or EC50 value
-
- C—CHEMISTRY; METALLURGY
- C07—ORGANIC CHEMISTRY
- C07K—PEPTIDES
- C07K2317/00—Immunoglobulins specific features
- C07K2317/90—Immunoglobulins specific features characterized by (pharmaco)kinetic aspects or by stability of the immunoglobulin
- C07K2317/94—Stability, e.g. half-life, pH, temperature or enzyme-resistance
Abstract
La presente divulgación proporciona proteínas de unión, tales como anticuerpos y fragmentos de unión a antígenos, que se unen específicamente a la proteína receptora CD200R1 humana (hu-CD200R1) y son capaces de disminuir, inhibir y/o bloquear completamente los efectos reguladores inmunitarios mediados por hu-CD200R1. La presente divulgación también proporciona métodos de uso de los anticuerpos (y composiciones de los mismos) para tratar enfermedades y afecciones que responden a la disminución, inhibición y/o bloqueo de la función o actividad reguladora inmunitaria mediada por la unión de CD200 a CD200R1.The present disclosure provides binding proteins, such as antibodies and antigen-binding fragments, that specifically bind to the human CD200R1 receptor protein (hu-CD200R1) and are capable of decreasing, inhibiting, and/or completely blocking immune-mediated regulatory effects. by hu-CD200R1. The present disclosure also provides methods of using the antibodies (and compositions thereof) to treat diseases and conditions that respond to the decrease, inhibition and/or blockade of immune regulatory function or activity mediated by the binding of CD200 to CD200R1.
Applications Claiming Priority (1)
Application Number | Priority Date | Filing Date | Title |
---|---|---|---|
US202063032508P | 2020-05-29 | 2020-05-29 |
Publications (1)
Publication Number | Publication Date |
---|---|
CL2022003296A1 true CL2022003296A1 (en) | 2023-04-14 |
Family
ID=76624182
Family Applications (1)
Application Number | Title | Priority Date | Filing Date |
---|---|---|---|
CL2022003296A CL2022003296A1 (en) | 2020-05-29 | 2022-11-23 | Anti-cd200r1 antibodies and methods of using the same |
Country Status (17)
Country | Link |
---|---|
US (2) | US11787861B2 (en) |
EP (1) | EP4157461A1 (en) |
JP (1) | JP2023528375A (en) |
KR (1) | KR20230018425A (en) |
CN (1) | CN116323665A (en) |
AR (1) | AR122213A1 (en) |
AU (1) | AU2021281417A1 (en) |
BR (1) | BR112022024339A2 (en) |
CA (1) | CA3178417A1 (en) |
CL (1) | CL2022003296A1 (en) |
CO (1) | CO2022016860A2 (en) |
CR (1) | CR20220608A (en) |
IL (1) | IL298668A (en) |
MX (1) | MX2022014736A (en) |
PE (1) | PE20230460A1 (en) |
TW (1) | TW202210512A (en) |
WO (1) | WO2021243204A1 (en) |
Families Citing this family (1)
Publication number | Priority date | Publication date | Assignee | Title |
---|---|---|---|---|
TW202400651A (en) * | 2022-05-19 | 2024-01-01 | 中國商和鉑醫藥(上海)有限責任公司 | Anti-CD200R1 antibodies |
Family Cites Families (72)
Publication number | Priority date | Publication date | Assignee | Title |
---|---|---|---|---|
US4676980A (en) | 1985-09-23 | 1987-06-30 | The United States Of America As Represented By The Secretary Of The Department Of Health And Human Services | Target specific cross-linked heteroantibodies |
US6548640B1 (en) | 1986-03-27 | 2003-04-15 | Btg International Limited | Altered antibodies |
IL85035A0 (en) | 1987-01-08 | 1988-06-30 | Int Genetic Eng | Polynucleotide molecule,a chimeric antibody with specificity for human b cell surface antigen,a process for the preparation and methods utilizing the same |
DE3883899T3 (en) | 1987-03-18 | 1999-04-22 | Sb2 Inc | CHANGED ANTIBODIES. |
IL87737A (en) | 1987-09-11 | 1993-08-18 | Genentech Inc | Method for culturing polypeptide factor dependent vertebrate recombinant cells |
EP0368684B2 (en) | 1988-11-11 | 2004-09-29 | Medical Research Council | Cloning immunoglobulin variable domain sequences. |
DE3920358A1 (en) | 1989-06-22 | 1991-01-17 | Behringwerke Ag | BISPECIFIC AND OLIGO-SPECIFIC, MONO- AND OLIGOVALENT ANTI-BODY CONSTRUCTS, THEIR PRODUCTION AND USE |
US5959177A (en) | 1989-10-27 | 1999-09-28 | The Scripps Research Institute | Transgenic plants expressing assembled secretory antibodies |
US6150584A (en) | 1990-01-12 | 2000-11-21 | Abgenix, Inc. | Human antibodies derived from immunized xenomice |
US6075181A (en) | 1990-01-12 | 2000-06-13 | Abgenix, Inc. | Human antibodies derived from immunized xenomice |
US5770429A (en) | 1990-08-29 | 1998-06-23 | Genpharm International, Inc. | Transgenic non-human animals capable of producing heterologous antibodies |
US5571894A (en) | 1991-02-05 | 1996-11-05 | Ciba-Geigy Corporation | Recombinant antibodies specific for a growth factor receptor |
LU91067I2 (en) | 1991-06-14 | 2004-04-02 | Genentech Inc | Trastuzumab and its variants and immunochemical derivatives including immotoxins |
GB9114948D0 (en) | 1991-07-11 | 1991-08-28 | Pfizer Ltd | Process for preparing sertraline intermediates |
US5587458A (en) | 1991-10-07 | 1996-12-24 | Aronex Pharmaceuticals, Inc. | Anti-erbB-2 antibodies, combinations thereof, and therapeutic and diagnostic uses thereof |
WO1993008829A1 (en) | 1991-11-04 | 1993-05-13 | The Regents Of The University Of California | Compositions that mediate killing of hiv-infected cells |
DE69334255D1 (en) | 1992-02-06 | 2009-02-12 | Novartis Vaccines & Diagnostic | Marker for cancer and biosynthetic binding protein for it |
EP0714409A1 (en) | 1993-06-16 | 1996-06-05 | Celltech Therapeutics Limited | Antibodies |
US5731168A (en) | 1995-03-01 | 1998-03-24 | Genentech, Inc. | Method for making heteromultimeric polypeptides |
US5869046A (en) | 1995-04-14 | 1999-02-09 | Genentech, Inc. | Altered polypeptides with increased half-life |
US6267958B1 (en) | 1995-07-27 | 2001-07-31 | Genentech, Inc. | Protein formulation |
US6171586B1 (en) | 1997-06-13 | 2001-01-09 | Genentech, Inc. | Antibody formulation |
US6040498A (en) | 1998-08-11 | 2000-03-21 | North Caroline State University | Genetically engineered duckweed |
US6610833B1 (en) | 1997-11-24 | 2003-08-26 | The Institute For Human Genetics And Biochemistry | Monoclonal human natural antibodies |
BR9813365A (en) | 1997-12-05 | 2004-06-15 | Scripps Research Inst | Method for Production and Humanization of a Mouse Monoclonal Antibody |
JP2002510481A (en) | 1998-04-02 | 2002-04-09 | ジェネンテック・インコーポレーテッド | Antibody variants and fragments thereof |
US6194551B1 (en) | 1998-04-02 | 2001-02-27 | Genentech, Inc. | Polypeptide variants |
US6737056B1 (en) | 1999-01-15 | 2004-05-18 | Genentech, Inc. | Polypeptide variants with altered effector function |
EP2264166B1 (en) | 1999-04-09 | 2016-03-23 | Kyowa Hakko Kirin Co., Ltd. | Method for controlling the activity of immunologically functional molecule |
AU5007200A (en) | 1999-05-13 | 2000-12-05 | Medical Research Council | Ox2 receptor homologs |
US7125978B1 (en) | 1999-10-04 | 2006-10-24 | Medicago Inc. | Promoter for regulating expression of foreign genes |
WO2001025454A2 (en) | 1999-10-04 | 2001-04-12 | Medicago Inc. | Method for regulating transcription of foreign genes in the presence of nitrogen |
US7504256B1 (en) | 1999-10-19 | 2009-03-17 | Kyowa Hakko Kogyo Co., Ltd. | Process for producing polypeptide |
DK2314686T4 (en) | 2000-10-06 | 2023-08-21 | Kyowa Kirin Co Ltd | Cells that form antibody complexes |
US7064191B2 (en) | 2000-10-06 | 2006-06-20 | Kyowa Hakko Kogyo Co., Ltd. | Process for purifying antibody |
US6946292B2 (en) | 2000-10-06 | 2005-09-20 | Kyowa Hakko Kogyo Co., Ltd. | Cells producing antibody compositions with increased antibody dependent cytotoxic activity |
US6596541B2 (en) | 2000-10-31 | 2003-07-22 | Regeneron Pharmaceuticals, Inc. | Methods of modifying eukaryotic cells |
KR100857943B1 (en) | 2000-11-30 | 2008-09-09 | 메다렉스, 인코포레이티드 | Transgenic Transchromosomal Rodents for Making Human Antibodies |
US7658921B2 (en) | 2000-12-12 | 2010-02-09 | Medimmune, Llc | Molecules with extended half-lives, compositions and uses thereof |
WO2003035835A2 (en) | 2001-10-25 | 2003-05-01 | Genentech, Inc. | Glycoprotein compositions |
US20040093621A1 (en) | 2001-12-25 | 2004-05-13 | Kyowa Hakko Kogyo Co., Ltd | Antibody composition which specifically binds to CD20 |
CA2481656A1 (en) | 2002-04-09 | 2003-10-16 | Kyowa Hakko Kogyo Co., Ltd. | Cells in which activity of the protein involved in transportation of gdp-fucose is reduced or lost |
AU2003236018A1 (en) | 2002-04-09 | 2003-10-20 | Kyowa Hakko Kirin Co., Ltd. | METHOD OF ENHANCING ACTIVITY OF ANTIBODY COMPOSITION OF BINDING TO FcGamma RECEPTOR IIIa |
US7691568B2 (en) | 2002-04-09 | 2010-04-06 | Kyowa Hakko Kirin Co., Ltd | Antibody composition-containing medicament |
US20040132140A1 (en) | 2002-04-09 | 2004-07-08 | Kyowa Hakko Kogyo Co., Ltd. | Production process for antibody composition |
EP1502603A4 (en) | 2002-04-09 | 2006-12-13 | Kyowa Hakko Kogyo Kk | DRUG CONTAINING ANTIBODY COMPOSITION APPROPRIATE FOR PATIENT SUFFERING FROM Fc gamma RIIIa POLYMORPHISM |
US20040110704A1 (en) | 2002-04-09 | 2004-06-10 | Kyowa Hakko Kogyo Co., Ltd. | Cells of which genome is modified |
US7361740B2 (en) | 2002-10-15 | 2008-04-22 | Pdl Biopharma, Inc. | Alteration of FcRn binding affinities or serum half-lives of antibodies by mutagenesis |
CN103833854B (en) | 2002-12-16 | 2017-12-12 | 健泰科生物技术公司 | Immunoglobulin variants and application thereof |
US20060104968A1 (en) | 2003-03-05 | 2006-05-18 | Halozyme, Inc. | Soluble glycosaminoglycanases and methods of preparing and using soluble glycosaminogly ycanases |
US7871607B2 (en) | 2003-03-05 | 2011-01-18 | Halozyme, Inc. | Soluble glycosaminoglycanases and methods of preparing and using soluble glycosaminoglycanases |
US20050106667A1 (en) | 2003-08-01 | 2005-05-19 | Genentech, Inc | Binding polypeptides with restricted diversity sequences |
CA2542046A1 (en) | 2003-10-08 | 2005-04-21 | Kyowa Hakko Kogyo Co., Ltd. | Fused protein composition |
CA2542125A1 (en) | 2003-10-09 | 2005-04-21 | Kyowa Hakko Kogyo Co., Ltd. | Process for producing antibody composition by using rna inhibiting the function of .alpha.1,6-fucosyltransferase |
WO2005053742A1 (en) | 2003-12-04 | 2005-06-16 | Kyowa Hakko Kogyo Co., Ltd. | Medicine containing antibody composition |
NZ547438A (en) | 2003-12-19 | 2010-01-29 | Genentech Inc | Monovalent antibody fragments useful as therapeutics |
ES2527292T3 (en) | 2004-03-31 | 2015-01-22 | Genentech, Inc. | Humanized anti-TGF-beta antibodies |
CA2885854C (en) | 2004-04-13 | 2017-02-21 | F. Hoffmann-La Roche Ag | Anti-p-selectin antibodies |
TWI309240B (en) | 2004-09-17 | 2009-05-01 | Hoffmann La Roche | Anti-ox40l antibodies |
SI1791565T1 (en) | 2004-09-23 | 2016-08-31 | Genentech, Inc. | Cysteine engineered antibodies and conjugates |
JO3000B1 (en) | 2004-10-20 | 2016-09-05 | Genentech Inc | Antibody Formulations. |
EP1934260B1 (en) * | 2005-10-14 | 2017-05-17 | Innate Pharma | Compositions and methods for treating proliferative disorders |
TW200732350A (en) | 2005-10-21 | 2007-09-01 | Amgen Inc | Methods for generating monovalent IgG |
US10155816B2 (en) | 2005-11-28 | 2018-12-18 | Genmab A/S | Recombinant monovalent antibodies and methods for production thereof |
CN101679519A (en) * | 2006-12-22 | 2010-03-24 | 先灵公司 | Antibodies to CD200R |
US20080226635A1 (en) | 2006-12-22 | 2008-09-18 | Hans Koll | Antibodies against insulin-like growth factor I receptor and uses thereof |
US20100325744A1 (en) | 2007-05-31 | 2010-12-23 | Genmab A/S | Non-glycosylated recombinant monovalent antibodies |
WO2008145138A1 (en) | 2007-05-31 | 2008-12-04 | Genmab A/S | Recombinant fucose modified monovalent half-antibodies obtained by molecular engineering |
MX350962B (en) | 2008-01-07 | 2017-09-27 | Amgen Inc | Method for making antibody fc-heterodimeric molecules using electrostatic steering effects. |
JP2011516840A (en) | 2008-04-04 | 2011-05-26 | トリリウム セラピューティクス インコーポレーティッド | Assay method for soluble CD200 |
WO2015057906A1 (en) | 2013-10-16 | 2015-04-23 | Janssen Biotech, Inc. | Cd200 receptor 1 agonists |
CA2874083C (en) * | 2014-12-05 | 2024-01-02 | Universite Laval | Tdp-43-binding polypeptides useful for the treatment of neurodegenerative diseases |
-
2021
- 2021-05-28 MX MX2022014736A patent/MX2022014736A/en unknown
- 2021-05-28 JP JP2022573152A patent/JP2023528375A/en active Pending
- 2021-05-28 US US17/333,963 patent/US11787861B2/en active Active
- 2021-05-28 KR KR1020227045305A patent/KR20230018425A/en unknown
- 2021-05-28 PE PE2022002743A patent/PE20230460A1/en unknown
- 2021-05-28 CA CA3178417A patent/CA3178417A1/en active Pending
- 2021-05-28 IL IL298668A patent/IL298668A/en unknown
- 2021-05-28 AU AU2021281417A patent/AU2021281417A1/en active Pending
- 2021-05-28 EP EP21735037.0A patent/EP4157461A1/en active Pending
- 2021-05-28 BR BR112022024339A patent/BR112022024339A2/en unknown
- 2021-05-28 WO PCT/US2021/034852 patent/WO2021243204A1/en unknown
- 2021-05-28 CN CN202180038994.4A patent/CN116323665A/en active Pending
- 2021-05-28 CR CR20220608A patent/CR20220608A/en unknown
- 2021-05-31 AR ARP210101465A patent/AR122213A1/en unknown
- 2021-05-31 TW TW110119701A patent/TW202210512A/en unknown
-
2022
- 2022-11-23 CL CL2022003296A patent/CL2022003296A1/en unknown
- 2022-11-24 CO CONC2022/0016860A patent/CO2022016860A2/en unknown
-
2023
- 2023-08-24 US US18/455,181 patent/US20240018239A1/en active Pending
Also Published As
Publication number | Publication date |
---|---|
EP4157461A1 (en) | 2023-04-05 |
WO2021243204A9 (en) | 2022-01-20 |
US11787861B2 (en) | 2023-10-17 |
AR122213A1 (en) | 2022-08-24 |
CO2022016860A2 (en) | 2023-02-27 |
AU2021281417A1 (en) | 2022-12-08 |
US20210371521A1 (en) | 2021-12-02 |
US20240018239A1 (en) | 2024-01-18 |
JP2023528375A (en) | 2023-07-04 |
PE20230460A1 (en) | 2023-03-10 |
CN116323665A (en) | 2023-06-23 |
CA3178417A1 (en) | 2021-12-02 |
BR112022024339A2 (en) | 2022-12-27 |
TW202210512A (en) | 2022-03-16 |
MX2022014736A (en) | 2023-03-23 |
CR20220608A (en) | 2023-01-26 |
IL298668A (en) | 2023-01-01 |
WO2021243204A1 (en) | 2021-12-02 |
KR20230018425A (en) | 2023-02-07 |
Similar Documents
Publication | Publication Date | Title |
---|---|---|
EA201891178A1 (en) | Bispecific molecules possessing immunoreactivity with respect to PD-1 and CTLA-4, and methods of their use | |
BR112018012352A2 (en) | anti-lag3 antibodies and antigen binding fragments | |
EA202092933A1 (en) | ANTIBODIES TO ENTPD2, TYPES OF COMBINATION THERAPY AND METHODS OF APPLICATION OF ANTIBODIES AND TYPES OF COMBINATION THERAPY | |
EA201792221A1 (en) | ANTIBODIES AGAINST SORTILINE AND METHODS OF THEIR APPLICATION | |
BR112018068898A2 (en) | antibody or fragment and its uses, transgenic animal, hybridoma, vector, pharmaceutical composition and its use, method for modulating a disease, method for treating weight loss, method for modulating activity | |
AR117327A1 (en) | ANTI-CD96 ANTIBODIES AND METHODS OF USE OF THEM | |
ECSP21010450A (en) | ANTI-SORTILINA ANTIBODIES AND METHODS FOR THEIR USE | |
EA201890145A1 (en) | ANTIBODIES TO FACTOR XI AND METHODS OF THEIR APPLICATION | |
BR112014018481A2 (en) | monoclonal or polyclonal antibody or antigen-binding fragment thereof, polynucleotide, monoclonal antibody, vector, hybridoma, antibody, hybridoma 5166-2 and / or 5166-9, antigen-binding antibody or fragment, pharmaceutical composition, antibody use or antibody binding fragment, method for treating cancer, method for diagnosing cancer in an individual, antibody, method, composition or use | |
BR112015030892A2 (en) | ANTIGEN-BINDING PROTEIN, MONOCLONAL ANTIBODY, RECOMBINANT NUCLEIC ACID, EXPRESSION VECTOR, HOST CELL, PHARMACEUTICAL COMPOSITION, USE OF AN ANTIGEN-BINDING PROTEIN OR HUMANIZED ANTIBODY, AND METHOD FOR PRODUCING AN ANTIGEN-BINDING PROTEIN | |
BR112015021979A2 (en) | HUMAN ANTIBODIES TO GREM1 | |
EA202091747A1 (en) | ANTIBODY B7-H4 COMPOSITIONS | |
EA201991546A1 (en) | ANTIGEN-BINDING PROTEINS AGAINST NEUROPILIN AND WAYS OF THEIR APPLICATION | |
CO2022000832A2 (en) | Anti-ms4a4a antibodies and methods of using them | |
BR112022009317A2 (en) | BIPARATOPIC CD73 ANTIBODIES | |
BR112022011570A2 (en) | ANTI-MERTK ANTIBODIES AND METHODS OF THEIR USE | |
CL2017002705A1 (en) | Antibodies that target bone morphogenic protein 9 (bmp9) and the methods to which they refer | |
EA202190138A1 (en) | ANTI-SIRP-BETA1 ANTIBODIES AND METHODS OF THEIR USE | |
BR112022002579A2 (en) | Antibodies against ilt2 and their use | |
CL2022003296A1 (en) | Anti-cd200r1 antibodies and methods of using the same | |
EA202190183A1 (en) | ANTIBODIES TO SIGLEC-5 AND METHODS OF THEIR APPLICATION | |
BR112017002173A2 (en) | angiopoietin-like antibodies and methods of use | |
EA202092125A1 (en) | ANTIBODIES AGAINST FOLATE 1 RECEPTOR AND THEIR APPLICATION | |
MX2022004058A (en) | Kir3dl3 is an inhibitory receptor of the immune system and uses thereof. | |
EA202092595A1 (en) | ANTIBODIES TO SIGLEC-7 AND METHODS OF THEIR APPLICATION |